Friday, September 13, 2013

Natural Human Interferon (Alpha-n3) is Active Against Both Wild-Type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus

PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that at the 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado during September 9-13, 2013, that William Mitchell, MD, Ph.D., Professor Pathology, Microbiology, and Immunology, Vanderbilt University, presented the results of a study of Hemispherx product, Alferon N Injection(R), the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, against wild type and oseltamivir (Tamiflu)-resistant H7N9 influenza virus.

The increasing prevalence of oseltamivir-resistant Influenza A Virus, particularly against H7N9, has been widely reported and is due in large part to the fact that just a single-step mutation in this genetically unstable virus makes it resistant to oseltamivir. Dr. Mitchell, who is member of the Board of Directors of Hemispherx, discussed new experiments on the inhibition of Tamiflu(R)-resistant H7N9 virus by Alferon N Injection(R).

These experiments were conducted at Kansas State University by Professor Juergen Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished Professor of Veterinary Medicine at Kansas State University and an Eminent Scholar of Kansas Bioscience Association (KBA) along with his staff.


No comments: